文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Martin P, Massol J, Soubrie P, Puech A J

Département de Pharmacologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France.

Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(5):735-48. doi: 10.1016/0278-5846(89)90061-4.

Daily injection of T3 during three consecutive days dose-dependently enhanced L-5-HTP (4 mg/kg)-induced head-twitches in mice. 2. Pretreatment with a sub-effective dose of T3 (0.06 mg/kg) markedly enhanced the ability of drugs acting mainly on noradrenergic systems (clenbuterol, desipramine, maprotiline and nomifensine) to increase the response to L-5-HTP. 3. In contrast the potentiating effects of T3 were moderate on drugs with mixed action on serotonergic and noradrenergic systems (amitriptyline, clomipramine and imipramine) and minimal on drugs acting mainly on serotonergic systems (citalopram, fluvoxamine and indalpine). 4. These data suggest that the increased responsiveness to L-5-HTP caused by T3 involves an indirect (norepinephrine-mediated) rather than a direct effect on serotonergic processes.

连续三天每日注射T3可剂量依赖性地增强L-5-羟色氨酸（4毫克/千克）诱导的小鼠头部抽搐。2. 用次有效剂量的T3（0.06毫克/千克）预处理可显著增强主要作用于去甲肾上腺素能系统的药物（克仑特罗、地昔帕明、马普替林和诺米芬辛）增加对L-5-羟色氨酸反应的能力。3. 相比之下，T3对作用于5-羟色胺能和去甲肾上腺素能系统的混合作用药物（阿米替林、氯米帕明和丙咪嗪）的增强作用中等，而对主要作用于5-羟色胺能系统的药物（西酞普兰、氟伏沙明和茚达品）的增强作用最小。4. 这些数据表明，T3引起的对L-5-羟色氨酸反应性增加涉及间接（去甲肾上腺素介导）而非对5-羟色胺能过程的直接作用。

Martin P, Massol J, Soubrie P, Puech A J

Département de Pharmacologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France.

Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(5):735-48. doi: 10.1016/0278-5846(89)90061-4.

Daily injection of T3 during three consecutive days dose-dependently enhanced L-5-HTP (4 mg/kg)-induced head-twitches in mice. 2. Pretreatment with a sub-effective dose of T3 (0.06 mg/kg) markedly enhanced the ability of drugs acting mainly on noradrenergic systems (clenbuterol, desipramine, maprotiline and nomifensine) to increase the response to L-5-HTP. 3. In contrast the potentiating effects of T3 were moderate on drugs with mixed action on serotonergic and noradrenergic systems (amitriptyline, clomipramine and imipramine) and minimal on drugs acting mainly on serotonergic systems (citalopram, fluvoxamine and indalpine). 4. These data suggest that the increased responsiveness to L-5-HTP caused by T3 involves an indirect (norepinephrine-mediated) rather than a direct effect on serotonergic processes.

连续三天每日注射T3可剂量依赖性地增强L-5-羟色氨酸（4毫克/千克）诱导的小鼠头部抽搐。2. 用次有效剂量的T3（0.06毫克/千克）预处理可显著增强主要作用于去甲肾上腺素能系统的药物（克仑特罗、地昔帕明、马普替林和诺米芬辛）增加对L-5-羟色氨酸反应的能力。3. 相比之下，T3对作用于5-羟色胺能和去甲肾上腺素能系统的混合作用药物（阿米替林、氯米帕明和丙咪嗪）的增强作用中等，而对主要作用于5-羟色胺能系统的药物（西酞普兰、氟伏沙明和茚达品）的增强作用最小。4. 这些数据表明，T3引起的对L-5-羟色氨酸反应性增加涉及间接（去甲肾上腺素介导）而非对5-羟色胺能过程的直接作用。